Gladman DD, Rigby WFC, Azevedo VF, et al. Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: OPAL BEYOND, a randomized, double-blind, placebo-controlled, phase 3 trial. EULAR 2017, OP0202.
Is DAS-remissie nog wel de juiste target?
aug 2022 | RA